Dynamic Changes in Erythrocyte 2,3 DPG as a Driver of Cardiac Dysfunction in End Stage Kidney Disease
Dynamic Changes in Erythrocyte 2,3 DPG as a Driver of Cardiac Dysfunction in End Stage Kidney Disease
批准号:
10662216
负责人:
Shilpa Sharma
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-07-01 至 2026-06-30
关键词:
AcuteAddressAffectAffinityAmericanApplications GrantsAreaAwardBiological MarkersBiometryBloodBone DiseasesBrain Hypoxia-IschemiaCardiovascular DiseasesCardiovascular systemCause of DeathCell membraneCellular biologyCessation of lifeChronic Kidney FailureClinicalClinical TrialsCritical IllnessDataData AnalysesDevelopmentDialysis patientsDialysis procedureDisease ProgressionEchocardiographyEducational workshopEnd stage renal failureErythrocytesEventExcess MortalityFormulationFundingFutureGeneral PopulationGoalsHealthcareHeartHemodialysisHemoglobinHypotensionHypotensivesHypoxiaImageImage AnalysisImaging TechniquesIn VitroInstitutionIronKidneyKidney DiseasesLaboratoriesLaboratory ResearchLeadLinkLos AngelesMagnetic ResonanceMaintenanceManuscriptsMeasuresMentorsMentorshipMetabolismMethodologyMineralsMorbidity - disease rateMyocardialMyocardial IschemiaMyocardial dysfunctionMyocardial tissueObservational StudyOutcomeOutpatientsOxygenPathogenesisPatientsPhosphorusPhysiciansPhysiologyPlayPopulationPreparationPrevalenceProductivityProspective StudiesRecordsRenal Replacement TherapyResearchResearch PersonnelResourcesRiskRisk FactorsScientistSerumTechniquesTemperatureTimeTissuesTrainingTranslationsUniversitiesVeteransWorkcardiovascular collapsecardiovascular imagingcareercareer developmentclinical investigationdesigndiphosphoglycerateexperimental studyextracellularhealth goalsheart imaginghemodynamicshigh riskhigh risk populationimprovedimproved outcomein vitro Modelinorganic phosphatemortalitymortality risknovelnovel therapeutic interventionpatient populationprogramsquantitative imagingskillstranslational studytreatment strategyultrasound
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
End-stage renal disease (ESRD) and its associated complications are disproportionately higher in
veterans compared to the general U. S. population. Approximately 45,500 veterans currently receive
hemodialysis. In the U.S., there is an estimated 500,000 ESRD patients receiving maintenance hemodialysis
and this number is predicted to rise to over 1 million by 2030. In veterans on dialysis, cardiovascular disease
is the leading cause of death and the risk of death is particularly high on the day of dialysis. The long-term
goal of the candidate is to conduct research that will lead to improved cardiovascular outcomes in dialysis
patients, a highly relevant goal for the health of American veterans. Research: This proposal will evaluate
novel mechanisms by which dialysis-driven risk factors contribute to cardiovascular disease. Dialysis-related
alterations in RBC phosphate metabolites lead to myocardial tissue hypoxia and intra-dialytic hypotension and
understanding the mechanisms of these changes should lead to new therapeutic strategies for ameliorating
cardiovascular mortality in this population. Specific Aim 1 will utilize an in vitro model to investigate dialysis
specific factors affecting 2,3-DPG concentrations.
Specific Aim 2 will examine the relationship between
changes in 2,3-DPG and hypotensive episodes during dialysis sessions. Specific Aim 3 will determine whether
changes in 2,3-DPG during dialysis are associated with myocardial dysfunction, utilizing a novel quantitative
imaging methodology based on real time echocardiography. Candidate: The program is designed to help Dr.
Sharma develop into an independent and productive researcher investigating cardiovascular complications of
chronic kidney disease, focusing on phosphate metabolism and eventually other aspects of chronic kidney
disease-mineral bone disorder (CKD-MBD), both topics highly relevant to the VA patient population. Dr.
Sharma's training objectives in this proposal include to: 1) develop expertise in the physiology of dialysis-
related alterations in erythrocyte 2,3-DPG associated with myocardial tissue hypoxia/ischemia and intra-dialytic
hypotension 2) develop expertise in interpretation, and advanced processing of multi-
parametric echocardiographic images 3) gain skills in laboratory techniques supporting translational studies as
well as related advanced bio-statistical approaches. Dr. Sharma will accomplish these activities through
studies supervised by her mentors, coursework, and participation in workshops. Mentors: Dr. Sharma has
assembled a team of accomplished scientists with proven track records in the mentorship of academicians
including her primary mentor- Dr. Kim-Lien Nguyen, who serves veterans as a non-invasive
cardiologist/cardiac imaging expert at the Greater Los Angeles VA and leads a productive, well-funded
cardiovascular imaging research laboratory focused on the development, translation, and application of
advanced cardiovascular imaging techniques, including echocardiography (ultrasound) and magnetic
resonance. Dr. Sharma's co-mentors are senior investigators and renowned in their respective fields: Dr.
Tomas Ganz (RBC biology and iron), Dr. Isidro Salusky (mineral metabolism and CKD), and Dr. Joachim Ix
(cardiovascular complications and CKD, Physician Scientist at VA San Diego). They will instruct and assist the
applicant during completion of the project, data analysis, manuscript preparation, and formulation of future
clinical trials and grant applications. Dr. Sharma will take didactic courses to obtain further training in
quantitative biomarker analyses, pertinent aspects of quantitative echocardiography and also obtain hands-on
training in image interpretation and relevant laboratory techniques. Dr. Sharma has the full support of her
institution, and her career development will benefit from ongoing partnerships with UCLA, a world-renowned
research university with a wide range of resources.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Elevated Fibroblast Growth Factor 23 Levels Are Associated With Greater Diastolic Dysfunction in ESRD.
成纤维细胞生长因子 23 水平升高与 ESRD 中更大的舒张功能障碍相关。
DOI:
10.1016/j.ekir.2019.07.022
发表时间:
2019
期刊:
Kidney international reports
影响因子:
6
作者:
[Sharma,Shilpa, Hanudel,MarkR, Ix,JoachimH, Salusky,IsidroB, Ganz,Tomas, Nguyen,Kim-Lien]
通讯作者:
Nguyen,Kim-Lien
Dynamic Changes in Erythrocyte 2,3 DPG as a Driver of Cardiac Dysfunction in End Stage Kidney Disease
-
批准号:10254626
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Shilpa Sharma
-
依托单位:
Dynamic Changes in Erythrocyte 2,3 DPG as a Driver of Cardiac Dysfunction in End Stage Kidney Disease
-
批准号:10426221
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Shilpa Sharma
-
依托单位:
海外基金